Medically reviewed by a licensed healthcare professional. Last updated March 2026.

Key Takeaways

  • The longest randomized controlled trial data we have for semaglutide is approximately 4 years (the SELECT cardiovascular outcomes trial) [1]. For tirzepatide, we have about 2 years of controlled data.
  • The most studied long-term concerns include thyroid C-cell tumors (seen in rodents but not confirmed in humans), pancreatitis, gallbladder disease, muscle loss, and bone density changes.
  • Real-world data from millions of patients since 2017 (when semaglutide was first approved as Ozempic) provides additional safety signals, though these are less rigorous than randomized trials.
  • Several long-term concerns are related to the weight loss itself, not the drug mechanism, meaning any effective weight loss intervention carries similar risks.
  • There is still much we don't know. GLP-1 medications for weight loss are relatively new, and 10+ year safety data does not exist yet.

How Much Long-Term Data Do We Actually Have?

This is the honest starting point. GLP-1 receptor agonists are not new. Exenatide (Byetta) was approved in 2005, and liraglutide (Victoza) in 2010, both for type 2 diabetes. Semaglutide was approved for diabetes as Ozempic in 2017 and for weight loss as Wegovy in 2021. Tirzepatide arrived as Mounjaro in 2022 and Zepbound in 2023.

So we have approximately 20 years of experience with GLP-1 medications as a drug class, but only about 4-5 years of widespread use at the higher doses prescribed for weight loss. Here is what the data shows for each concern.

Thyroid Cancer: The Rodent Study Question

What the Warning Says

Every GLP-1 medication carries a boxed warning about thyroid C-cell tumors. This warning exists because rodent studies (in rats and mice) showed that GLP-1 receptor agonists caused medullary thyroid carcinoma (MTC) when given at high doses for long periods [2].

What the Human Data Shows

The critical context: rats have significantly more GLP-1 receptors on their thyroid C-cells than humans do, and their C-cells respond to GLP-1 stimulation differently [3].

Human data so far is reassuring:

  • The SELECT trial (semaglutide, 17,604 patients, median follow-up 3.4 years) found no increased risk of MTC [1].
  • A 2023 meta-analysis of GLP-1 RA trials covering 60,000+ patients found no statistically significant increase in thyroid cancer [4].
  • 20 years of post-marketing surveillance from earlier GLP-1 medications (liraglutide, exenatide) has not revealed a thyroid cancer signal in humans.
  • A large Nordic registry study following 145,000+ GLP-1 RA users found no increased thyroid cancer risk over 7 years of follow-up [5].

What we still don't know: Whether 10-20 years of continuous high-dose GLP-1 exposure could increase MTC risk in humans. MTC is extremely rare (about 0.5 cases per 100,000 people per year), so detecting a small increase would require enormous sample sizes and long follow-up.

Practical guidance: GLP-1 medications are contraindicated in people with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2). For everyone else, current evidence does not support avoiding GLP-1 medications because of thyroid cancer concerns.

Pancreatitis Risk

What the Data Shows

Pancreatitis (inflammation of the pancreas) has been a concern since the earliest GLP-1 medications. The relationship is complicated because obesity and type 2 diabetes are themselves major risk factors for pancreatitis [6].

Clinical trial data:

  • In the STEP trials, acute pancreatitis occurred in about 0.2% of semaglutide users, similar to placebo [7].
  • The SELECT trial reported pancreatitis in 0.18% of semaglutide users vs. 0.10% of placebo users, a difference that was not statistically significant [1].
  • SURMOUNT trials for tirzepatide showed similar low rates [8].

Post-marketing data: The FDA FAERS database has received pancreatitis reports associated with GLP-1 medications, but these are difficult to interpret because obesity itself increases pancreatitis risk by 2-3 times [6].

Practical guidance: The risk is low but real. Stop GLP-1 medications immediately and contact your provider if you experience severe, persistent abdominal pain radiating to your back, especially with nausea and vomiting. Do not restart a GLP-1 medication after confirmed pancreatitis without specialist guidance.

Gallbladder Disease

This is one of the more established long-term risks and is likely related to rapid weight loss rather than the drug mechanism itself.

Why GLP-1 Medications Increase Gallbladder Risk

Rapid weight loss from any cause (medication, diet, bariatric surgery) increases the risk of gallstones. When you lose weight quickly, the liver secretes extra cholesterol into bile, and the gallbladder contracts less frequently due to reduced food intake. Both factors promote gallstone formation [9].

How Common Is It?

  • In the STEP trials, cholelithiasis (gallstones) occurred in 1.6% of semaglutide users vs. 0.7% in placebo [7].
  • Cholecystitis (gallbladder inflammation) occurred in about 0.6% of semaglutide users.
  • SURMOUNT trials showed similar rates for tirzepatide [8].
  • Bariatric surgery patients face gallstone rates of 30-40%, consistent with even more rapid weight loss [10].

Practical guidance: Symptoms of gallbladder problems include right-sided abdominal pain (especially after fatty meals), nausea, and sometimes fever. Report these to your provider promptly. Some providers recommend ursodiol (a bile acid medication) for patients with a history of gallstones who are losing weight rapidly.

Muscle Loss and Body Composition

The Concern

All weight loss, regardless of method, involves some degree of lean mass loss alongside fat loss. On average, 25-40% of weight lost through caloric restriction alone is lean mass (muscle, bone, water) [11]. The concern with GLP-1 medications is that the significant appetite suppression may make it harder to eat enough protein to preserve muscle.

What Studies Show

  • The STEP 1 extension study showed that after 68 weeks on semaglutide, approximately 39% of weight lost was lean mass [7]. This is within the typical range for non-surgical weight loss.
  • A SURMOUNT-1 sub-study using DEXA scans found that about 33% of weight lost on tirzepatide was lean mass [8].
  • Importantly, patients who incorporated resistance training during GLP-1 therapy lost significantly less muscle, with some studies showing lean mass loss as low as 15-20% of total weight lost [12].

Practical guidance: Muscle loss on GLP-1 medications is preventable with adequate protein (0.7-1.0g per pound of lean body mass daily) and resistance training 2-3 times per week. This is not optional. See our guide on preventing muscle loss on GLP-1 medications.

Bone Density Changes

What We Know

Weight-bearing mass protects bones. When you lose significant weight, the mechanical load on your skeleton decreases, which can reduce bone mineral density. This is especially concerning for postmenopausal women and older adults [13].

  • The STEP trials did not include routine DEXA scans, so systematic bone density data is limited.
  • Bariatric surgery data (a reasonable comparison for significant weight loss) shows 5-10% bone density reduction in the first 2 years post-surgery [14].
  • A 2024 retrospective study of GLP-1 users found a modest decrease in bone mineral density that was proportional to weight lost [15].

Practical guidance: If you are losing significant weight on GLP-1 medications, consider baseline and annual DEXA scans, ensure adequate calcium and vitamin D intake, and incorporate weight-bearing exercise. This is particularly important for women over 50 and anyone with osteoporosis risk factors.

Other Long-Term Considerations

B12 Deficiency

GLP-1 medications may reduce vitamin B12 absorption over time. Metformin (which many GLP-1 users also take) further increases this risk. Long-term users should have B12 levels monitored annually [16].

Gastroparesis

Chronic slowing of gastric emptying raises the question of whether long-term GLP-1 use could cause or worsen gastroparesis. Case reports exist, but systematic data is lacking. The FDA updated labeling in 2023 to include ileus (intestinal slowdown) as a potential adverse event [17].

Mental Health

Some GLP-1 users report mood changes, including depression and anxiety. The FDA investigated these reports in 2023 and found no definitive causal link, but continues to monitor [18]. The European Medicines Agency conducted a similar review with the same conclusion.

Kidney Function

GLP-1 medications may actually be protective for kidney function. The FLOW trial (semaglutide in diabetic kidney disease) showed reduced progression of kidney disease [19]. However, dehydration from GI side effects can temporarily worsen kidney function, so adequate hydration is essential.

What We Still Don't Know

It is important to be honest about the gaps in our knowledge:

  • 10+ year safety data on high-dose semaglutide/tirzepatide does not exist. We are in uncharted territory for chronic use at weight-loss doses.
  • Effects of stopping and restarting. Many patients cycle on and off GLP-1 medications. The long-term impact of this pattern is unknown.
  • Generational effects. We don't know whether GLP-1 exposure before or during early pregnancy (accidental exposure) has long-term effects on offspring.
  • Cancer risk beyond thyroid. Some researchers are investigating whether GLP-1 medications affect risk for pancreatic, colorectal, or breast cancer. Early data is mixed and inconclusive.
  • Very long-term body composition. What happens to muscle mass and bone density after 5-10 years of GLP-1 therapy, even with exercise and protein, is unknown.

The Risk-Benefit Equation

Every medication involves a trade-off. For GLP-1 medications, the known benefits are substantial:

  • 15-25% body weight reduction [7][8]
  • 20% reduction in major cardiovascular events (SELECT trial) [1]
  • Improved blood sugar control, blood pressure, and lipids
  • Reduced sleep apnea severity
  • Improved quality of life and mobility

These benefits need to be weighed against the known risks (GI side effects, gallbladder disease, muscle loss) and the unknown long-term risks outlined above.

For most people with obesity and related health conditions, the current evidence strongly favors the benefits. But this is a conversation to have with your healthcare provider based on your individual risk profile, not a decision to make from a blog post alone.

Frequently Asked Questions

Is it safe to take GLP-1 medications for life?

The honest answer is that we don't have lifetime safety data yet. The longest controlled trial data is about 4 years (SELECT trial for semaglutide). However, the GLP-1 drug class has been used for diabetes since 2005 without major unexpected long-term safety signals emerging. Your provider can help you weigh the benefits of continued use against the uncertainties.

Do GLP-1 medications cause cancer?

There is no confirmed cancer risk in humans from GLP-1 medications. The thyroid cancer concern comes from rodent studies and has not been replicated in human data spanning 20 years and hundreds of thousands of patients. Ongoing surveillance continues.

What happens to your body after years on semaglutide?

Based on available data, most people maintain weight loss, continued cardiovascular benefits, and stable metabolic health. The main considerations are maintaining muscle mass through exercise and protein, monitoring bone density, and staying hydrated. Annual comprehensive bloodwork is recommended.

Should I take breaks from GLP-1 medication?

There is no evidence that "drug holidays" provide safety benefits. When GLP-1 medications are stopped, weight typically returns within 12-18 months. If you are considering stopping, discuss a gradual tapering plan with your provider rather than abruptly discontinuing.

Are newer GLP-1 medications safer than older ones?

Not necessarily safer, but better studied. Semaglutide and tirzepatide were tested in larger trials with more rigorous safety monitoring than earlier GLP-1 medications. They also benefit from 20 years of class-level safety data from predecessor drugs.

Ready to start your weight loss journey? Find a GLP-1 clinic near you and connect with a qualified provider today.

Sources

  1. SELECT Trial: Semaglutide Cardiovascular Outcomes, NEJM (2023)
  2. Thyroid C-Cell Effects of GLP-1 RAs in Rodents, Endocrinology (2010)
  3. GLP-1 Receptor Expression in Human vs. Rodent Thyroid, Thyroid (2015)
  4. Meta-Analysis: GLP-1 RAs and Thyroid Cancer Risk, Diabetes Care (2023)
  5. Nordic Registry: GLP-1 RA Use and Thyroid Cancer, The Lancet Diabetes & Endocrinology (2024)
  6. Obesity and Pancreatitis Risk, Pancreas (2019)
  7. STEP 1 and STEP 1 Extension: Semaglutide Long-Term Data, NEJM (2021-2022)
  8. SURMOUNT-1 and SURMOUNT-3: Tirzepatide Long-Term Data, NEJM (2022-2023)
  9. Gallstone Formation During Rapid Weight Loss, Hepatology (2016)
  10. Gallstones After Bariatric Surgery, Obesity Surgery (2020)
  11. Body Composition Changes During Weight Loss, AJCN (2018)
  12. Resistance Training Preserves Lean Mass During GLP-1 Therapy, Obesity (2024)
  13. Weight Loss and Bone Mineral Density, JBMR (2017)
  14. Bone Health After Bariatric Surgery, Endocrine Reviews (2020)
  15. GLP-1 RA Use and Bone Density: Retrospective Analysis, JCEM (2024)
  16. B12 Deficiency in GLP-1 RA Users, Diabetes, Obesity and Metabolism (2023)
  17. FDA Updates GLP-1 RA Labeling for GI Events (2023)
  18. FDA Review: GLP-1 Medications and Mental Health (2023)
  19. FLOW Trial: Semaglutide in Diabetic Kidney Disease, NEJM (2024)

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.